Price
No data yet.
Social Signal Score
Analyst Ratings
Company Profile
- CEO
- Miles Harrison
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- 0.51
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
CNXUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·3d ago·Neutral
Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors RENO, Nev., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a preclinical-stage regenerative tissue platform company, today announced the appointment of Daniel M. Bradbury as Chairman of the Board of Directors, effective December 1, 2026.
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Conexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R. Conexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice, Fabricated Formats of Its Investigational CXU™ Platform
View source ↗ - Newsglobenewswire.com·38d ago·Negative
Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing scale-up, regulatory testing and preclinical work toward the Company's planned FDA 510(k) submission in the first quarter of 2027 Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing scale-up, regulatory testing and preclinical work toward th
View source ↗ - Newsglobenewswire.com·47d ago·Negative
Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an investigational tissue-restoration platform, today provided an update on the regulatory and manufacturing program supporting its planned U.S. Food and Drug Administration (“FDA”) 510(k) premarket notification for Ten …
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
Conexeu Sciences Sets September and October 2026 Conference Schedule RENO, Nev., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage biotechnology company advancing an investigational tissue-restoration platform, is pleased to announce its participation in the following investor and industry conferences during September and October 2026.
View source ↗ - Newsglobenewswire.com·96d ago·Neutral
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu's CXU™ Platform
View source ↗
Earnings
Fri, Jan 22(in 2 months)
Consensus estimate $-0.11 per share
Typical surprise -95.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Sep 14$-0.29 vs $-0.10miss
- Mon, Jun 15$-0.11 vs $-0.11beat
Estimates and results for CNXU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CNXU officers and directors.
- Bought
- $1.6m
- Sold
- —
4 trades
0 trades
- Purcell Lynn Sebastianbought
- Purcell Lynn Sebastianbought
- Purcell Lynn Sebastianbought
- Purcell Lynn Sebastianbought
39 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CNXU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
